DROXIA
Total Payments
$70,000
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $10,000 | 1 | 0 |
| 2017 | $60,000 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $70,000 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Realizing Effectiveness Across Continents with Hydroxyurea REACH A Phase I II Study of Hydroxyurea for Children with Sickle Cell Anemia | E.R. Squibb & Sons, L.L.C. | $60,000 | 0 |
| Realizing Effectiveness Across Continents with Hydroxyurea REACH A Phase III Study of Hydroxyurea for Children with Sickle Cell Anemia | E.R. Squibb & Sons, L.L.C. | $10,000 | 0 |
Top Doctors Receiving Payments for DROXIA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cincinnati, OH | $70,000 | 2 |
Ad
Manufacturing Companies
- E.R. Squibb & Sons, L.L.C. $70,000
Product Information
- Type Drug
- Total Payments $70,000
- Total Doctors 0
- Transactions 2
About DROXIA
DROXIA is a drug associated with $70,000 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2017 to 2019. In 2019, $10,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for DROXIA is "Unspecified" ($70,000, 100.0% of total).
DROXIA is associated with 2 research studies, including "Realizing Effectiveness Across Continents with Hydroxyurea REACH A Phase I II Study of Hydroxyurea for Children with Sickle Cell Anemia" ($60,000).